ORACLE: Observation of ResiduAl Cancer with Liquid biopsy Evaluation (CTMS# 22-0052)
This research is being done to see if an investigational blood test can predict whether cancer will recur (come back) after initial treatment
This research is being done to see if an investigational blood test can predict whether cancer will recur (come back) after initial treatment
Manage Your Cancer Risk
At Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, our team pioneered the use of intensity-modulated radiation therapy (IMRT) decades ago. Today, our experts use IMRT to treat certain cancers, such as prostate and lung cancers, with incredible precision. IMRT’s increased effectiveness — with fewer side effects — offers new possibilities for what you can do during and after cancer treatment.
This is an international, multicenter, open-label, randomized, Phase 3 study in patients with locally advanced, inoperable, or metastatic triple-negative breast cancer (mTNBC) who have not received previous therapy for advanced disease and whose tumors are PD-L1 positive (defined using the PD-L1 IHC 22C3 assay as tumors with a combined positive score [CPS] ≥ 10) at screening.
This study evaluates the preliminary efficacy and safety of NIS793 and other novel investigational combinations with SOC anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of metastatic colorectal cancer.
Diagnosing Cancer
Our Cancer Programs
Childhood Cancer Survivorship Program
Patient and Family Services During Cancer Care
Radiation Oncology